Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler, Emmanuel S. Antonarakis(Sidney Kimmel Comprehensive Cancer Center), Andrew J. Armstrong(Cancer Institute (WIA)), Anthony V. D’Amico(Dana-Farber Brigham Cancer Center), Brian J. Davis, Tanya B. Dorff(City Of Hope National Medical Center), James A. Eastham(Memorial Sloan Kettering Cancer Center), Charles A. Enke(Susan Thompson Buffett Foundation), Thomas A. Farrington(Education and Research Network), Celestia S. Higano(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Eric M. Horwitz(Fox Chase Cancer Center), Michael E. Hurwitz(Yale Cancer Center), Joseph E. Ippolito(Barnes-Jewish Hospital), Christopher J. Kane(University of California San Diego), Michael Kuettel, Joshua M. Lang(University of Wisconsin Carbone Cancer Center), Jesse K. McKenney(Cleveland Clinic), George J. Netto(University of Alabama at Birmingham), David F. Penson(Breast Cancer Research Foundation), Elizabeth R. Plimack(Fox Chase Cancer Center), Julio M. Pow‐Sang(Moffitt Cancer Center), Thomas J. Pugh(University of Colorado Cancer Center), Sylvia Richey(St. Jude Children's Research Hospital), Mack Roach(UCSF Helen Diller Family Comprehensive Cancer Center), Stan Rosenfeld(UCSF Helen Diller Family Comprehensive Cancer Center), Edward M. Schaeffer(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Ahmad Shabsigh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Eric J. Small(UCSF Helen Diller Family Comprehensive Cancer Center), Daniel E. Spratt(University of Michigan), Sandy Srinivas(Cancer Institute (WIA)), Jonathan D. Tward(University of Utah), Dorothy A. Shead(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network)
Cited by 1,571Open Access
Abstract
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.